STAT3 and neoplasm: Additionally, MDSCs enhance metastasis by promoting β-adrenergic signaling and the IL-6–STAT3 pathway and can differentiate into osteoclasts in bone metastatic cancers, thereby contributing to bone destruction and promoting tumor growth [49].